Enspryng: payments to doctors
Payments that named Enspryng as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1M
- Providers
- 2,959
- Transactions
- 11,054
- Average per transaction
- $94
The per-transaction average — $94 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 2,959 providers the average total is $350, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech USA, Inc. | $662,330 | 63.9% |
| Genentech, Inc. | $213,076 | 20.6% |
| F. Hoffmann-la Roche AG | $143,216 | 13.8% |
| Chugai Pharmaceutical Co., Ltd. | $11,408 | 1.1% |
| Hoffmann-la Roche Limited | $4,450 | 0.4% |
| Roche Products Limited | $1,463 | 0.1% |